Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1

Juha Peltonen

Status: Unknown

Conditions: Neurofibromatosis 1

Treatments: Other: Blood sample

Study type: Observational

Funder types: Other

Identifiers

NCT02680431

141-1801-2015

Details and patient eligibility

About

The purpose of this study is to find blood plasma based biomarkers of disease progression in neurofibromatosis type 1 (NF1). NF1 is associated with the development of benign cutaneous tumors as well as a variety of malignancies. Analysis of plasma DNA and chemical composition may provide tools for diagnosis and follow-up of NF1. The hypothesis of the study is that NF1-associated tumor burden and malignant transformation of tumors can be detected in plasma. To test this hypothesis, Finnish patients with NF1 are recruited and blood sample is taken. Blood plasma is separated and analyzed chemically. DNA is then also extracted and quantified.

Full description

Neurofibromatosis type 1 (NF1) is a dominant hereditary multiorgan disease that causes both benign cutaneous neurofibromas and malignant tumors. Timely detection of malignant transformation in NF1 tumors is of great clinical importance. Also methods to easily monitor individual's overall tumor burden would be useful. Blood plasma is collected from NF1 patients and age- and gender-matched controls. The samples are stored at -80 C until analysis. Free circulating plasma DNA is extracted and quantified using commercial reagents. Also a previously described chemical detection method to observe overall changes in plasma composition is utilized. The analysis results are compared between NF1 patients and healthy controls, and also correlated with NF1 tumor burden and diagnosis of malignancy during five-year follow-up.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Finnish-speaking
• 18-85 years old
• For NF1 group: Diagnosis of type 1 neurofibromatosis and visit to Turku Neurofibromatosis Centre
• For control group: Suitable as an age- and gender-matched control for some of the NF1 patients

Exclusion criteria

• Non-Finnish-speaking
• For control group: diagnosis of neurofibromatosis type 1 or cancer

Trial design

100 participants in 2 patient groups

Neurofibromatosis 1

Description:

10 mL venous blood sample taken from patients with type 1 neurofibromatosis

Treatment:

Other: Blood sample

Control

Description:

10 mL venous blood sample taken from age- and gender-matched healthy controls

Treatment:

Other: Blood sample